Atlas Trials

A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)

Clinical trial NCT02964338 · TERMINATED

Trial details

NCT number
NCT02964338
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Cluster Headache
Start date
2017-01-17
Primary completion
2018-07-18
Enrollment
259

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.